In this episode, topics include: * Drug therapy for patients that fail standard therapy; including surgery and RAI * Not all patients have same behavior for their cancer * Some cancers are aggressive * Not many thyroid cancer patients are affected by this; maybe a few thousand in the U.S., but not tens of thousands * What is the treatment protocol for therapy? * Lenvatinib or Sorafenib is the treatment for refectory thyroid cancer * Lenvatinib tends to be more effective * Sorafenib is tolerated by the patient better * Other options to consider include, molecular profiling or some thyroid cancers carry mutation that is targetable, or BRAF * BRAF inhibitors used with thyroid cancer patients * Molecular profiling * DNA sequencing
Dr. Bridget Brady is Austin's first fellowship-trained endocrine surgeon. In this episode the following topics are discussed: Austin Thyroid Surgeons sees 30 patients per week with thyroid nodules Up to 80% of US population could have a thyroid nodule(s) less than 5% of Dr Brady's thyroid nodule patients test positive for cancer How relevant is what I don’t know won’t hurt me in thyroid cancer and biopsies of nodules? BETHESDA system or the middle category, also known as indeterminate For thyroid nodules that are indeterminate, historically a surgery would be performed With molecular testing, surgery can be decreased by up to 50% Afirma molecular testing uses messenger RNA If Afirma comes back suspicious it does NOT necessarily mean it is cancer
Not all thyroid cancer patients who receive a thyroidectomy require radioactive iodine, but for those whose cancer maybe more aggressive and spread beyond the thyroid area, often radioactive iodine (RAI) is protocol. RAI treatment may vary depending on the hospital. In this interview, Dr. Alan Waxman explains what occurs leading up to, during, and after RAI. Topics discussed include: If staying at the hospital after taking RAI, how long is the stay required? Should you go home after RAI? What is the benefit of staying overnight at the hospital when receiving RAI? Worldwide trends toward prescribing lower doses of RAI. Is there risk in RAI causing leukemia?
In this episode Dr. Bansal shares the research she presented at AACE 2017 and ENDO 2017, regarding the poor readability scores for thyroid cancer web sites. The challenge for these web sites and health institutions is to translate thyroid education from complex to simple and easy to understand. Currently, many patients are not following up with treatment, citing confusion after being exposed to the various thyroid cancer education resources.
What Happens When Thyroid Cancer Travels to the Lungs? In this interview, Dr. Fabian Pitoia discusses the treatment for distant metastatic thyroid cancer. Topics discussed include: 10% of thyroid cancer patients will have distant metastatic disease The disease will travel to lungs, bones, or both Treatment with RAI is most effective for those under 40 years old Evaluation of metastatic thyroid cancer in the lungs is a CT scan In 2006, there was a change in the treatment of the disease
Managing thyroid cancer in children, sometimes more complex than adults In this episode Dr. Bauer shares the complexities of managing children with thyroid nodules, and differentiated thyroid cancer. This is a must listen interview for parents whose child has a thyroid nodule or thyroid cancer diagnosis. There are a several important differences in how pediatric thyroid nodules and differentiated thyroid cancer (DTC) present and respond to therapy. Kids are less frequently diagnosed with a thyroid nodule; however, the risk for malignancy is four- to fivefold higher compared with an adult thyroid nodule.
El Dr Fabián Pitoia es Médico Endocrinólogo, es Jefe de la Sección Tiroides y Coordinador del Área Investigación de la División Endocrinología del Hospital de Clínicas - Universidad de Buenos Aires. En esta entrevista, discutiremos: Los síntomas que una experiencia del paciente puede saber que tienen un problema Si cirugía siempre es una necesidad Cuándo se quita sólo la mitad de la tiroides?